News

Gritstone bio and CEPI expand vaccine agreement to tackle Omicron variant

CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone’s Omicron vaccine candidate in South Africa.

06 Dec 2021

Trial & regulatory procedures

Making vaccines available for use in 100 days will require a paradigm shift in these areas of vaccine development.

29 Nov 2021

Boosting vaccine manufacturing

Compressing vaccine development timelines to 100 days will require a step-change in how we manufacture vaccines.

29 Nov 2021

Global surveillance networks

Dedicated global surveillance of high-risk pathogens can speed identification of Disease X, which will be crucial to achieving the 100 days mission.

29 Nov 2021

100 Days

The world can face down the next Disease X with a new vaccine in just 100 days. Here’s how…

29 Nov 2021

Rapid-response vaccine technology

Development of rapid-response vaccine technology will be crucial in enabling the world to achieve the 100 days mission.

29 Nov 2021

Vaccine libraries

Creation of vaccine libraries will help the world develop vaccines against the next Disease X in 100 days.

29 Nov 2021

1 2 3 4 5 6